$6.19
+0.15 (+2.40%)
Open$5.96
Previous Close$6.05
Day High$6.19
Day Low$5.94
52W High$15.15
52W Low$3.31
Volume—
Avg Volume49.4K
Market Cap6.85M
P/E Ratio—
EPS$-0.50
SectorBiotechnology
Analyst Ratings
Strong Buy
7 analysts
Price Target
+221.2% upside
Current
$6.19
$6.19
Target
$19.88
$19.88
$13.54
$19.88 avg
$24.91
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 9.7K | 9.7K | 653.1K |
| Net Income | -571,625 | -509,419 | 116.0K |
| Profit Margin | -5,863.7% | -5,570.5% | 17.8% |
| EBITDA | -584,091 | -549,446 | 172.6K |
| Free Cash Flow | — | — | 101.3K |
| Rev Growth | +1.0% | +1.0% | -9.1% |
| Debt/Equity | — | — | 0.30 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $254.31 | +0.38% | 118.2 | 429.58B |
| AMGN | Amgen Inc | $360.55 | +0.62% | 24.8 | 193.10B |
| GILD | Gilead Sciences Inc | $126.33 | -1.21% | 17.1 | 157.21B |
| VRTX | Vertex Pharmaceuticals Inc | $499.65 | +1.69% | 28.1 | 121.87B |
| REGN | Regeneron Pharmaceuticals | $631.81 | -0.17% | 15.0 | 66.35B |
| ALNY | Alnylam Pharmaceuticals Inc | $293.52 | +0.74% | 69.3 | 39.97B |